高级搜索
食管癌高表达抗原HLA-A2/A3 限制性细胞毒性T 淋巴细胞表位预测[J]. 肿瘤防治研究, 2007, 34(06): 412-415. DOI: 10.3971/j.issn.1000-8578.3219
引用本文: 食管癌高表达抗原HLA-A2/A3 限制性细胞毒性T 淋巴细胞表位预测[J]. 肿瘤防治研究, 2007, 34(06): 412-415. DOI: 10.3971/j.issn.1000-8578.3219
Prediction of HLA-A2/3 Restricted Cytototxic T Lymphocyte Epitopes in Hyper-expressed Antigens in Esophageal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2007, 34(06): 412-415. DOI: 10.3971/j.issn.1000-8578.3219
Citation: Prediction of HLA-A2/3 Restricted Cytototxic T Lymphocyte Epitopes in Hyper-expressed Antigens in Esophageal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2007, 34(06): 412-415. DOI: 10.3971/j.issn.1000-8578.3219

食管癌高表达抗原HLA-A2/A3 限制性细胞毒性T 淋巴细胞表位预测

Prediction of HLA-A2/3 Restricted Cytototxic T Lymphocyte Epitopes in Hyper-expressed Antigens in Esophageal Carcinoma

  • 摘要: 目的 预测食管癌普遍高表达蛋白COX-2和MAGE-4的HLA-A2/A3限制性CTL表位。方法运用生物信息学的方法,SYFPEITHI初步预测,结合三维构效定量关系和蛋白酶体酶切位点分析。结果 对SYFPEITHI预测〉20的九肽用MHCPred和NetChop3.0作进一步分析,并与已报道抗原肽进行比对,初步筛选出了42个潜在的CTL表位。结论 这42个九肽均未见文献报道,进一步鉴定将为CTL表位疫苗的研究提供更多的线索。其中,MAGE-422-30、202-210、286-294及COX-2479-4874个九肽具有与HLA-A2和HLA-A3超型潜在的交叉免疫活性,将为研制简约的高效广谱食管癌疫苗提供候选肽。

     

    Abstract: Objective  To predict the HLA-A2/A3-rest ricted CTL epitopes of COX-2 and MAGE-4 hyperexpressed in esophageal carcinoma ( ECC) . Methods  The HLA-A *0201/A3 rest ricted CTL epitopes of objective antigens were predicted by SYFPEITHI prediction method combined with the MHCPred and NetChop 3. 0. All peptides were compared with reported CTL epitopes. Results  The SYFPEITHI prediction values of all possible nonamers of the two proteins sequence were added together and the over 20-score peptides were chosen for further analysis in primary prediction. 42 candidates of CTL epitopes (nonamers) derived from the primary prediction results were selected by analyzing with the MHCPred and NetChop3. 0 methods. Conclusion  All these peptides have not been reported. The 42 candidates of CTL epitopes will benefit the identification of CTL epitopes by experiment . These nonamers may be useful in the design of therapeutic peptide vaccine for ECC and as immunotherapeutic st rategies against ECC after identified by immunology experiment . The peptides MAGE-4 22-30202-210286-294 and COX-2 479-487 have the potential cross-immunity with HLA-A2 and HLA-A3 supertype, which will provide candidates for efficient and broad-spectrum vaccine.

     

/

返回文章
返回